Importantly, we also found that SLC30A10 inhibits the Mn-clearing function of ATP2C1, revealing a novel mechanism with respect to Mn metabolism and creating new opportunities for treating HMDPC and related conditions. Here, SLC30A10 is linked to cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome.